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Objectives. The purpose of this study was to prospectively 
assess the effect of dynamic cardiomyoplasty in patients with 
symptomatic hronic heart failure. 
Background. Since the first procedure was performed in 1985, 
dynamic cardiomyoplasty has been developed for use in patients 
with chronic heart failure. The aging population in developed 
countries has made heart failure a growing public health concern. 
Heart transplantation is appropriate or available for only a small 
proportion of these patients because of limited donor supply. 
Effective alternatives to transplantation are needed. 
Methods. Eight centers in North and South America performed 
68 cardiomyoplasty procedures between May 1991 and September 
1993. Data were prospectively collected every 6 months and 
compared with preoperative values using paired t tests, chi-square 
tests and actuarial survival analyses. 
Results. Patients had a mean (-+SD) age of 57 -+ 1 years and 
were predominantly male (53 [78%] of 68). Heart failure etiology 
was classified as idiopathic in 47 (69%) of 68 patients and 
ischemic in 21 (31%). The in-hospital mortality rate was 12% (8 of 
68), and the survival rate at 6 and 12 months was 75 _+ 5% and 
68 -+ 6%, respectively. Objective improvements were seen at 6 
months (n = 49) in left ventricular ejection fraction (23 -+ 1% vs. 
25 -+ 1%, p = 0.05), stroke volume (50 -+ 2 vs. 56 -+ 3 ml/beat, p = 
0.02) and left ventricular stroke work index (26 -+ 1 vs. 30 -+ 
2 g/m 2 per beat, p = 0.01). Improvements in mean New York Heart 
Association functional class (3 + 0.04 vs. 1.8 _+ 0.1, p = 0.0001) 
and activity of daily living score (59 -+ 3 vs. 80 -+ 2, p = 0.0001) 
were also observed. There were no significant changes at 6 months 
in peak oxygen consumption (15 +- 1 vs. 16 -+ 1 ml/kg per rain), 
cardiac index (2.26 -+ 0.08 vs. 2.33 -+ 0.08 liters/min per m2), 
pulmonary capillary wedge pressure (19 ± 2 vs. 18 -+ 1 mm Hg) 
or heart rate (87 -+ 2 vs. 82 -+ 3 beats/rain). 
Conclusions. These data suggest hat dynamic cardiomyoplasty 
improves ventricular systolic function, reduces symptoms of heart 
failure and improves objective measures of quality of life in 
patients with congestive heart failure. This improvement occurred 
without changes in peak exercise capacity, ventricular filling 
pressure or actuarial survival. 
(J Am CoU Cardiol 1996;28:1175-80) 
Each year -400,000 people in the United States are added to 
the population of 2.3 million patients already diagnosed with 
heart failure. Approximately 2,300 heart transplantations are 
performed in the United States annually. Most of the remain- 
ing patients are managed with medical therapy. Despite signif- 
icant advances in the pharmacologic treatment of heart failure, 
many patients realize little improvement in quality of life or 
cardiac morbidity, and mortality rates are still high. Adjuvant 
therapies to enhance the quality of life of these terminally ill 
patients are still needed. Dynamic cardiomyoplasty is one 
possible therapy. 
Dynamic ardiomyoplasty is a surgical procedure in which a 
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pedicled latissimus dorsi muscle flap is transposed into the 
chest and wrapped around the ventricles of a failing heart. The 
muscle flap is then electrically stimulated to contract in 
synchrony with ventricular systole. Latissimus dorsi muscle 
stimulation is incrementally increased over a period of 10 
weeks, causing gradual transformation of muscle fibers from 
Type II (anaerobic, fatigue prone) to Type I (aerobic, fatigue 
resistant) fibers. 
Clinical dynamic ardiomyoplasty is the result of >50 years 
of scientific advancements in our understanding of anatomy, 
muscle physiology and microcircuit technology. In the 1930s, 
several surgeons began experimenting with skeletal muscle 
repair of the heart (1-3). In the 1950s, Kantrowitz and 
McKinnon (4) stimulated iaphragm muscle wrapped around 
the aorta and demonstrated increased blood flow for a short 
period before muscle fatigue. In the 1960s, independent efforts 
in Europe by Termet et al. (5) and in the United States by 
Hume (6) led to the use of electrically stimulated latissimus 
dorsi wrapped around the heart. Meanwhile, Buller et al. (7) 
used cross-innervation studies to demonstrate that muscles 
could be transformed from "fast-twitch" fatigable to "slow- 
twitch" fatigue-resistant fibers. In the 1970s, Salmons and 
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Streter (8) showed that this same muscle transformation could 
be accomplished using electrical stimulation. Macoviak et al. 
(9) experimentally applied this concept using single-pulse 
stimulation of the diaphragmatic pedicle graft to the heart in 
laboratory animals. DeWar and Chiu (10) later incorporated 
the concept that multiple, sequential electrical pulses (a 
"pulse-train") greatly increased muscle recruitment and power, 
and they worked with Medtronic, Inc. to develop an external 
cardiomyostimulator f r use in the procedure. These advance- 
ments culminated in the first clinical application of dynamic 
cardiomyoplasty in 1985 in Paris, France by Carpentier and 
Chachques (11) using a fully implantable system. 
Between 1985 and 1991,-185 cardiomyoplasty procedures 
were performed in 17 countries worldwide. Reports published 
during this period documented significant, subjective, clinical 
improvements; objective improvements were inconsistently 
noted or were often not reproduced (12-16). The present 
study, approved by the U.S. Food and Drug Administration 
(FDA), was designed to more objectively quantify the efficacy 
of dynamic ardiomyoplasty. 
Methods  
Study organization. The FDA-approved Phase II study 
was conducted at five U.S. centers, two Canadian centers and 
one Brazilian center (see Appendix). Data were collected and 
analyzed centrally. A steering committee, consisting of princi- 
pal investigators from each center, developed and imple- 
mented the protocol. A clinical events review committee, 
consisting of investigators and independent consultants, eval- 
uated all deaths and monitored the progress of the study. The 
study was approved by the institutional review boards of each 
hospital, and the patients gave written informed consent. 
Patient eligibility. Patients were eligible for the study if 
they 1) had heart failure due to dilated cardiomyopathy or
ischemic heart disease that had not improved espite attempts 
to optimize drug therapy; 2) were in New York Heart Associ- 
ation functional class III; 3) had left ventricular ejection 
fraction (LVEF) by radionuclide ventriculography <40%; 4) 
had left ventricular end-diastolic pressure or pulmonary capil- 
lary wedge pressure _>15 mm Hg; and 5) had an intact 
latissimus dorsi muscle. 
Patients were excluded from the study if they 1) were <18 
or >80 years old; 2) had arrhythmias requiring a pacemaker or 
implantable cardioverter-defibrillator; 3) had poor lung func- 
tion with forced vital capacity <55% of predicted value; 4) 
were dependent on intravenous inotropes; 5) had a life- 
threatening noncardiac disease; 6) had creatinine clearance 
<30 ml/min; or 7) had unresolved rug or alcohol abuse. 
Study protocol. Patients underwent dynamic cardiomyo- 
plasty as a single-stage procedure in which the left latissimus 
dorsi muscle was wrapped around the heart in a posterior 
cardiocostal or cardiosubcutaneous fashion (17). A variance in 
operative technique was allowed for 13 patients treated with 
right latissimus anterior cardiocostal myoplasty (17) at a single 
center. Analyses comparing the right and left latissimus car- 
diomyoplasty subgroups howed no clinically relevant preop- 
erative or postoperative differences. Therefore, the two groups 
were combined for these analyses. 
Ten-week muscle stimulation protocol was designed to 
gradually transform the latissimus dorsi from Type II to Type 
I fatigue-resistant muscle. Details of the surgical and latissimus 
dorsi stimulation techniques have been described elsewhere 
(18-20). 
Every 6 months postoperatively the patients repeated the 
following preoperative tests: radionuclide ventriculography, 
right heart catheterization, respiratory gas exchange with con- 
comitant exercise testing, chest X-ray film, 12-lead electrocar- 
diogram, 24-h Holter monitor, functional class and a quality of 
life questionnaire (21). In addition to results of these tests, 
investigators also reported medications, complications and 
hospital admissions during each evaluation period. 
Each center in the study was also asked to enroll nonran- 
domized, medically treated reference patients from their med- 
ically treated heart failure population with the following 
characteristics: heart failure due to dilated cardiomyopathy or 
ischemic heart disease; functional class Ill; LVEF by radionu- 
clide ventriculography <40%; age between 18 and 80 years. 
These patients were assessed at 6-month intervals using the 
same quality of life questionnaire and were likewise followed 
up with respect o survival, hospital admission rate, functional 
class and medication use. 
Statistical analysis. Data were analyzed using SAS soft- 
ware. There were no statistical adjustments for multiple test- 
ing. Paired t tests were used to test improvement in continuous 
variables over time. Two-sample t tests were used to compare 
the treatment and reference group baseline characteristics and 
improvements over time. The Fisher exact and chi-square tests 
were used on dichotomous and polyehotomous variables, 
respectively. Survival curves were produced using the actuarial 
(life table) method and compared by the Mantel-Haenszel test. 
Results  
Patients. Sixty-eight patients underwent dynamic cardio- 
myoplasty between May 1991 and September 1993. The pa- 
tients were 56.6 _+ 1.4 years old, and were predominantly male 
(78%). The etiology of heart failure was classified as idiopathic 
in 47 (69%) and ischemic in 21 (31%). Their mean functional 
class was 3.00 + 0.03, and mean duration of heart failure 
symptoms was 3.6 years. A history of arrhythmias was reported 
in 36 patients (53%), and atrial fibrillation was present in 13 
(19%). At the time of enrollment, all patients were receiving 
digoxin and diuretic drugs, and 61 (90%) were taking 
angiotensin-converting enzyme inhibitors. Other vasodilators 
were used in place of angiotensin-converting e zyme inhibitors 
in three of the remaining seven patients. Fourteen patients 
(21%) received long-term antiarrhythmic therapy. 
Table 1 details the preoperative measurements of cardiac 
performance and exercise tolerance for all 68 postoperative 
patients. Left ventricular ejection fraction by radionuclide 
ventriculography was 21.9 _+ 0.8%. Baseline cardiac index was 
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Table 1. Preoperative Measurements of Cardiac Performance and 
Exercise Tolerance in 68 Study Patients 
Mean ± SE 
Functional assessment 
NYHA 3.00 _+ 0.03 
Peak Vo 2 (ml/kg per rain) 14.8 + 0.6 
Radionuclide measures 
LVEF (%) 21.9 _+ 0.8 
RVEF (%) 40.9 _+ 2.4 
Hemodynamic measures 
HR (beats/rain) 85.7 _+ 1.7 
CI (liters/rain per m 2) 2.26 _+ 0.06 
LVEDP (ram Hg) 22.1 _+ 1.1 
PCWP (ram Hg) 20.1 -+ 1.1 
MPAP (ram Hg) 29.6 _+ 1.3 
SV (ml/beat) 52.0 + 1.9 
LVSWI (g.m/m z per beat) 24.6 _+ 1.3 
CI - cardiac index; HR = heart rate: LVEDP = left ventricular end- 
diastolic pressure: LVEF - left ventricular ejection fraction; LVSWI left 
ventricular stroke work index; MPAP = mean pulmonary artery pressure; 
NYHA - New York Heart Association functional class: PCWP = pulmonary 
capillary wedge pressure: RVEF = right ventricular ejection fraction: SV = 
stroke volume; Vo z = oxygen uptake. 
2.26 _+ 0.06 liters/rain per m 2, with a concomitant pulmonary 
capillary wedge pressure of 20.1 + 1.1 mm Hg. Peak oxygen 
consumption during exercise testing was 14.8 _+ 0.6 ml/kg per 
min. 
Table 2 compares the patients who underwent dynamic 
cardiomyoplasty with the reference patients. 
Operative data. Of the 68 patients who underwent dynamic 
cardiomyoplasty, 3 had a concomitant surgical procedure 
(coronary artery bypass grafting in 2, mitral valve repair in 1). 
The postoperative mortality rate was 12% (8 of 68), and death 
occurred at a median of 11 days. Causes of death included 
primary cardiac failure (6 patients), aspiration pneumonia (1 
patient) and sepsis (1 patient). 
Table 2. Preoperative Demographic and Quality, of Life Scores for 
Patients Undergoing Cardiomyoplasty and Reference Patients 
Reference 
Cardiomyoplasty Group 
Group (n = 68) (n = 58) p Value 
Age (yr) 56.6 _+ 1.4 57.0 _+ 1.3 0.85 
Male 78% 78% 1.00 
Etiology 0.53 
Ischemic 31% 36% 
Idiopathic 69% 64% 
NYHA 3.00 + 0.03 2.98 +_ 0.0 0.42 
LVEF 21.9 + 0.8 20.2 + 0.9 0.18 
Quality of life scores 
ADL 59.4 _+ 2.4 64,4 _+ 3.2 0.20 
Social activity 46.0 _+ 4.1 52.7 _+ 4.9 0.29 
Quality, of interaction 76.4 _+ 2.5 76.l _+ 2.3 0.93 
Mental health 67.2 + 2.5 67.3 _+ 2.9 0.97 
Data presented are mean value _+ SE or percent of patients. ADL = basic 
activities of daily living; other abbreviations a  in Table l. 
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Figure l. Actuarial survival curve for the 68 patients undergoing 
cardiomyoplasty versus 58 reference patients drawn from seven of the 
eight investigation sites. DCMP = dynamic ardiomyoplasty. 
A total of 13 additional patients (13 [19%] of 68) experi- 
enced one or more major, nonfatal postoperative complica- 
tions (20 complications in total). Four patients (4 [6%] of 68) 
developed severe hemodynamic deterioration requiring inser- 
tion of an intraaortic balloon pump. One of these four patients 
failed to hemodynamically recover and underwent successful 
cardiac transplantation at 1.4 months postoperatively. Seven 
patients (7 [10%] of 68) required prolonged mechanical ven- 
tilation or reintubation. Six patients (6 [9%] of 68) required 
defibrillation, cardioversion or overdrive pacing. Two patients 
(2 [3%] of 68) required dialysis, and one (1 [1%] of 68) 
developed sepsis. 
Six. and 12-month evaluation. Figure 1 depicts the actuar- 
ial survival curve for the 68 postoperative patients compared 
with 58 reference patients over a 2-year period. There was no 
significant difference in survival between the treatment and 
reference groups at any time point during the 12-month 
evaluation period. 
Measurements of cardiac performance and exercise capac- 
ity for the surviving patients are shown in Table 3. Significant 
improvements were seen in LVEF by radionuclide ventricu- 
lography, stroke volume and left ventricular stroke work index 
at 6 and 12 months. By 12 months, heart rate was also 
significantly lower. Subjective assessment tools also indicated a
significant improvement in heart failure symptoms; functional 
class significantly decreased, and the basic activities of daily 
living score increased. This was, likewise, a persistent finding 
through the first 12 months. There was no change in peak 
aerobic apacity as measured by peak oxygen consumption. 
Discuss ion  
Study rationale. To our knowledge, this report represents 
the results of the first multicenter study designed to investigate 
the short and long-term effects of dynamic ardiomyoplasty in 
patients with chronic heart failure. Earlier experience at single 
institutions has helped to define patient selection and opera- 
tive technique. In 1991, Grandjean et al. (12) reported on 78 
patients operated on between 1985 and 1990, 46% of whom 
had functional class IV heart failure. Twelve percent of 
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Table 3. Postoperative M asures of Cardiac Performance and Exercise Tolerance 
12-Month Comparison 
No. of Pts Preop (mean ± SE) 12 mo (mean _+ SE) No. of Pts 
6-Month Comparison 
Preop (mean + SE) 6 mo (mean ± SE) 
Functional assessment 
NYHA 32 3.0 ± 0.1 1.7 = 0.1" 49 
Peak "Vo 2 (ml/kg per min) 29 15.8 ± 0.8 16.0 _+ 1.1 44 
Radionuclide measures 
LVEF (%) 31 22.7 ± 1.0 25.5 + 1.9" 49 
RVEF (%) 24 40.3 _+ 3.9 40.8 ± 3.9 42 
Hemodynamic measures 
HR (beats/min) 23 87.2 _+ 2.8 79.1 + 3.3* 41 
CI (liters/'min per m 2) 31 2.26 ± 0.1 2.37 ± 0.1 46 
PCWP (mm Hg) 22 19.2 ± 1.9 20.4 ± 1.5 41 
MPAP (mm Hg) 31 28.8 ± 1.8 32.0 _+ 1.8' 47 
SV (ml/beat) 31 48.2 ± 2.4 56.9 ± 3.6* 45 
LVSWI (g.m/m z per beat) 23 25.0 _+ 1.7 31.8 ± 2.9* 41 
3.0 ± 0.04 1.8 ± 0.1' 
15.4 -+ 0.7 15.8 ± 0.9 
22.7 ± 0.9 24.6 ± 1.3" 
40.9 ± 3.0 41.3 ± 3.0 
86.6 _+ 2.0 82.2 _+ 2.7 
2.26 + 0.1 2.33 ± 0.1 
19.0 ± 1.5 18.1 ± 1.3 
27.6 _+ 1.5 27.8 ± 1.4 
50.0 z 2.3 55.7 ± 2.9* 
25.8 ÷ 1.5 30.0 ± 1.8" 
*p < 0.05 versus preoperative (Preop) values; Bonferroni's correction was not applied. Pts = patients; other abbreviations a in Table 1. 
patients in functional class III and 33% of those in class IV 
died during the initial hospital stay. Notwithstanding, func- 
tional status improvement was observed in 85% of the surviv- 
ing patients despite the investigators' inability to demonstrate 
salutary hemodynamic changes. In contrast, Moreira et al. 
(22,23), from Sao Paulo, Brazil, have consistently detailed 
hemodynamic improvement. Moreover, they have shown (15) 
significant and beneficial changes in exercise tolerance, as well 
as survival, in a nonrandomized trial. Carpentier et al. (24) 
published a review of their 52-patient experience, citing an 
early mortality rate of 54% during 1985 to 1987 and 12% 
during 1988 to 1992, with a late mortality rate of 20%. A subset 
of patients showed an improved LVEF, but no change in 
cardiac filling pressure; functional class was markedly en- 
hanced in the survivors. Thus, at the onset of the present study, 
investigators worldwide had noted a prohibitively high mortal- 
ity rate in functional class IV patients. This finding was 
frustrating in light of the fact that these same patients were the 
most likely to benefit from the procedure. However, because a
safe clarification of the effects of cardiomyoplasty on cardiac 
performance and quality of life, including exercise tolerance 
was needed, the present multicenter trial was restricted to 
patients with functional class III heart failure. 
The present study involved 68 patients who entered into a 
protocol that was similarly followed by investigators at eight 
institutions. Patients were, by selection, somewhat less hemo- 
dynamically compromised than those in previous tudies and 
had moderately severe heart failure, as evidenced by an LVEF 
of 21.9 _+ 0.8% and a peak oxygen uptake of 14.8 _+ 0.6 ml/kg 
per rain. Correspondingly, the in-hospital mortality rate was 
lower at 12%. Some measurements of cardiac performance 
indicated significant improvement, including a sustained in- 
crease in LVEF and augmentation f stroke volume and stroke 
work index. Perhaps more important, an objective assessment 
of quality of life suggested a significant lessening of heart 
failure symptoms, with a simultaneous enhancement of well- 
being. 
Study significance. The clinical significance of these results 
should be determined by the same criteria that are used to 
judge the etficacy of heart failure therapy. The view that the 
syndrome of congestive heart failure secondary to dilated 
cardiomyopathy is primarily one of central hemodynamic 
abnormalities has evolved in the past decade (25). Earlier 
efforts to improve cardiovascular hemodynamic variables at 
rest did not always result in a reduction of patient symptoms 
(26). Subsequently it was thought hat a therapeutic agent must 
improve cardiovascular hemodynamic variables not only at rest 
but also during exertion for the agent to have a meaningful 
effect (27). However, multiple drugs failed to effect sustained 
clinical benefit during large-scale, controlled trials (28). The 
current hypothesis argues that hemodynamic alterations are 
not the only pathophysiologic abnormality in heart failure that 
must be corrected for a therapeutic agent to be successful. 
Alterations in skeletal muscle metabolism, local vascular tone, 
respiratory muscle function and neurohormonal responses 
must all be normalized. 
How, then, should a therapy for heart failure be judged? 
Perhaps most important, definitive trials must be undertaken 
in a placebo-controlled or case-controlled, randomized man- 
ner (29), which was not done in the present study. One valid 
criticism of the present study might be the nonrandomized 
nature of our control group. In addition, other factors not 
easily accounted for may make the treatment and reference 
groups noncomparable. Accordingly, arandomized trial design 
is currently under way for the cardiomyoplasty procedure. 
In addition to definitive controlled trials, multiple end 
points must be analyzed. Patient symptoms, often legion in 
heart failure, can be chronicled subjectively and objectively. An 
accurate measurement of aerobic capacity, the peak oxygen 
uptake has been shown to reflect hemodynamic status (30) and 
predict clinical stability (31) and survival (32) in patients with 
heart failure. Measurement of LVEF has become routine in 
heart failure trials, although it has infrequently been shown to 
improve (33,34). However, improvement in LVEF, when it has 
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occurred, has correlated with improved survival (33,34). Fi- 
nally, and ultimately, survival of the patient with heart failure 
must be prolonged if a therapeutic approach is to be judged 
efficacious. 
Using these criteria, the cardiomyoplasty procedure was an 
effective therapy for the patients in the present study. Patients 
undergoing cardiomyoplasty had reduced symptoms and an 
improved LVEF. Peak oxygen uptake, although not improved, 
was maintained for at least 1 year. Survival was not measured 
against a randomized, control cohort but was as good as a 
reference group collected at the investigating centers. These 
data certainly complement an earlier study showing enhanced 
survival (15). 
Mechanistic hypotheses. If dynamic cardiomyoplasty is a 
beneficial therapy for patients with chronic heart failure, which 
of the potential mechanisms of action are responsible for the 
benefit observed? Various hypotheses have been suggested. 
Lee et al. (35) proposed that the muscle wrap acts to reduce 
left ventricular wall stress and thereby augments myocardial 
shortening. Capouya et al. (36), as well as Mott et al. (37), 
suggested that the procedure serves to halt progressive l ft 
ventricular dilation. Both proposals would be consistent with 
the observed ata (i.e., little change in cardiac filling pressures 
but alterations in volume-pressure lation and stability of 
exercise tolerance). Single-center reports also support these 
concepts. In the largest single-center series to date, Carpentier 
et al. (24) reported a stable cardiothoracic ratio up to 3 years 
after cardiomyoplasty. Moreira et al. (38) reported clinical 
evidence of reduced wall stress, reduced left ventricular cham- 
ber stiffness and increased left ventricular maximal elastance 
after cardiomyoplas~. Kass et al. (39) reported a striking 
clinical benefit associated with reverse chamber remodeling in 
three case studies using pressure-volume analysis. 
Some researchers have shown (22,23,40,41) that a loss of 
muscle integrity in the cardiomyoplasty flap correlates with a 
lack of hemodynamic efficacy, underscoring the importance of 
this central mechanism for the procedure. Ongoing research is 
addressing long-term muscle optimization (42-45). Also relat- 
ing to latissimus dorsi contribution, several reports (46-51) 
have been recently published on the ability of optimal stimu- 
lation timing to significantly improve outcome in cardiomyo- 
plasty. 
Patient selection. As with any new operative procedure, 
considerable exploration i to proper patient selection must be 
undertaken, both to reduce surgical risk and to improve 
long-term outcome (52). A better understanding of surgical 
risk in cardiomyoplasty is emerging from several single-center 
publications (13,22,23,37,53-55) and multicenter analyses 
(56,57); the largest multicenter report to date (57) with a total 
of 166 patients includes the 68 patients from the present 
report. With regard to long-term outcomes, it is possible that a 
certain stage of heart failure may be altered more successfully 
by cardiomyoplasty. Alternatively, dynamic cardiomyoplasty 
may be most efficacious when used in conjunction with con- 
comitant surgical procedures, uch as high risk coronary bypass 
procedures or repair of regurgitant lesions. Many of these 
issues remain unresolved. 
Conclusions. Dynamic cardiomyoplasty may improve 
symptoms and cardiac performance in patients with chronic 
heart failure. Operative techniques have been refined, and 
optimal patient selection has resulted in decreased hospital 
mortality. The ultimate role of this procedure for the thou- 
sands of patients with dilated cardiomyopathy awaits the 
results of the current case-controlled, randomized trial. 
Appendix 
Participating Centers and Investigators 
Allegheny General Hospital, Pittsburgh, Pennsylvania: George Magovern, 
St., MD (Principal Investigator), James Magoveru, MD, Ignaco Christlieb, MD. 
St. Vincent Hospital, Portland, Oregon: Albert Starr, MD (Principal Investiga- 
tor), Jeffrey Swanson, MD, Anthony Furnary, MD. Institnto do Coraljao, Sao 
Paulo, Brazil: Noedir Stolf, MD (Principal Investtgator), Luiz Moreira, MD, Adib 
Jatene, MD, Edimar Bocchi, MD. Philadelphia Heart Institute of the Presby- 
terian Medical Center, Philadelphia, Pennsylvania: James Sink, MD (Principal 
Investigator), Mariell Jessup, MD, Charles Gotflieb, MD, Diana DiMarzio, RN, 
Kathleen DiLeva, RN. Cleveland Clinic Foundation, Cleveland, Ohio: Delos 
Cosgrove, MD (Principal Investigator), Robert Hobbs, MD, Roberto Novoa, MD. 
Montreal General Hospital, Montreal, Quebec, Canada: Ray Chiu, MD (Prin- 
cipal Investigator), Jonah Odim, MD, John Burgess, MD. Johns Hopkins 
Hospital, Baltimore, Maryland: Kenneth Baughman, MD (Principal Investiga- 
tor), Timothy Gardner, MD, Michael Acker, MD, Edward Kasper, MD. Univer- 
sity of Western Ontario, London, Ontario, Canada: Gerard Guiraudon, MD 
(Principal Investigator), William Kostuk, MD, Larry Chow, MD. 
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